
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is des... Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B. We believe that the blockade of GSK-3B signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. We have exclusively licensed a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago (UIC) and Northwestern University (NU). Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.59 | -6.41304347826 | 9.2 | 9.35 | 8.24 | 34124 | 8.71221917 | CS |
4 | -1.18 | -12.0531154239 | 9.79 | 11.99 | 8.24 | 71976 | 10.4212378 | CS |
12 | 1.81 | 26.6176470588 | 6.8 | 11.99 | 6.1 | 59596 | 9.28488117 | CS |
26 | 0.54 | 6.69144981413 | 8.07 | 11.99 | 6.02 | 49439 | 8.6995777 | CS |
52 | 3.61 | 72.2 | 5 | 11.99 | 5 | 40807 | 8.49499013 | CS |
156 | 3.61 | 72.2 | 5 | 11.99 | 5 | 13548 | 8.49499013 | CS |
260 | 3.61 | 72.2 | 5 | 11.99 | 5 | 8688 | 8.49499013 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions